Targeted Therapy and Immunotherapy in Melanoma
- PMID: 36410984
- DOI: 10.1016/j.det.2022.07.007
Targeted Therapy and Immunotherapy in Melanoma
Abstract
While metastatic melanoma still carries significant mortality rates, the introduction of targeted therapy with BRAF/MEK inhibition and immunotherapy with PD-1, PD-L1, and CTLA-4 inhibitors has led to significant strides in outcomes and prognosis.
Keywords: Immunotherapy; Melanoma; Targeted; Therapy.
Copyright © 2022 Elsevier Inc. All rights reserved.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials